Genmab shares dropped 5.9% after its Phase 3 EPCORE DLBCL-1 trial for epcoritamab failed to meet a key secondary endpoint. The study in relapsed/refractory DLBCL patients showed improved progression-free survival but missed statistical significance for overall survival, a critical measure for regulatory approval.

The trial evaluated the bispecific antibody against standard chemotherapy in 483 patients. While the therapy showed benefits in response rates and duration, the overall survival miss represents a significant setback for the drug's commercial potential in this competitive oncology space.

Genmab and partner AbbVie will now engage regulators to discuss next steps. The companies are pursuing additional Phase 3 trials, with data expected in 2026. The outcome underscores the high bar for new lymphoma therapies and may prompt a strategic reevaluation of the program's scope.